Albumin sales key to Novozymes biopharma biz gains in H1

Related tags Revenue

Novozymes, recombinant albumin, hyaluronidase
Higher revenue from recombinant albumin hyaluronic acid helped Novozymes’ biopharmaceutical business in the first half of 2012, but the firm expects growth to slow in the second half of the year. 

Last week Novozymes reported first half revenue from its biopharma business of DKK77m ($13m), up from DKK51m in the comparable period last year, roughly one per cent of the DKK5.8bn of total revenue it recorded in the six months to the end of June 2012.

Novozymes said that growth was achieved despite the divestiture of its biopharma unit in Sweden to Repligen late last year​, citing increased sales of recombinant albumin, positive timing effects between quarters and sales from its new hyaluronic acid facility in China​ as drivers.


For the rest of the year Novozymes predicted that revenue growth in its biopharmaceutical business will slow down

Biopharma sales grew very strongly in Q2 2012, partly due to timing between quarters, and, as a result, growth rates in Biopharma will decelerate in the second half of 2012.

The firm also said that the Swedish divestiture will continue to have a negative impact and predicted that – as a result - sales would be around DKK90m lower in the second half of 2012 than they were in the year earlier period.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more